ArticleOncotarget2015
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer.
Wing-yin Leung et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this papercites it